Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease.
Alzheimer patients were treated with lecithin and gradually increasing doses of oral physostigmine during a drug trial to determine if these compounds would improve memory. Memory was measured using a selective reminding task. Of 16 patients, 10 showed improvement in total recall, retrieval from long-term storage and a decrease in intrusions. The optimal dose was 2.0 mg or 2.5 mg of physostigmine per dose for most patients. During a replication study, all 10 patients again responded. During long-term (4 to 20 months) treatment of five patients, most demonstrated continued drug response initially but then lost responsiveness to physostigmine and their dementia progressed. Physostigmine treatment appeared to improve memory with or without concomitant lecithin therapy. However, progressive dementia ensued despite physostigmine therapy. The degree of memory improvement correlated with increasing cerebrospinal fluid cholinesterase inhibition suggesting that memory improvement is associated with entry of physostigmine into the brain.
D000284:Administration, Oral; D000544:Alzheimer Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008568:Memory / Q000187:drug effects; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D010830:Physostigmine / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D013997:Time Factors
D010713:Phosphatidylcholines; D010830:Physostigmine